Cargando…
COVID-19 forecasting using new viral variants and vaccination effectiveness models
Recently, a high number of daily positive COVID-19 cases have been reported in regions with relatively high vaccination rates; hence, booster vaccination has become necessary. In addition, infections caused by the different variants and correlated factors have not been discussed in depth. With large...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381972/ https://www.ncbi.nlm.nih.gov/pubmed/36030722 http://dx.doi.org/10.1016/j.compbiomed.2022.105986 |
_version_ | 1784769195944181760 |
---|---|
author | Rashed, Essam A. Kodera, Sachiko Hirata, Akimasa |
author_facet | Rashed, Essam A. Kodera, Sachiko Hirata, Akimasa |
author_sort | Rashed, Essam A. |
collection | PubMed |
description | Recently, a high number of daily positive COVID-19 cases have been reported in regions with relatively high vaccination rates; hence, booster vaccination has become necessary. In addition, infections caused by the different variants and correlated factors have not been discussed in depth. With large variabilities and different co-factors, it is difficult to use conventional mathematical models to forecast the incidence of COVID-19. Machine learning based on long short-term memory was applied to forecasting the time series of new daily positive cases (DPC), serious cases, hospitalized cases, and deaths. Data acquired from regions with high rates of vaccination, such as Israel, were blended with the current data of other regions in Japan such that the effect of vaccination was considered in efficient manner. The protection provided by symptomatic infection was also considered in terms of the population effectiveness of vaccination as well as the vaccination protection waning effect and ratio and infectivity of different viral variants. To represent changes in public behavior, public mobility and interactions through social media were also included in the analysis. Comparing the observed and estimated new DPC in Tel Aviv, Israel, the parameters characterizing vaccination effectiveness and the waning protection from infection were well estimated; the vaccination effectiveness of the second dose after 5 months and the third dose after two weeks from infection by the delta variant were 0.24 and 0.95, respectively. Using the extracted parameters regarding vaccination effectiveness, DPC in three major prefectures of Japan were replicated. The key factor influencing the prevention of COVID-19 transmission is the vaccination effectiveness at the population level, which considers the waning protection from vaccination rather than the percentage of fully vaccinated people. The threshold of the efficiency at the population level was estimated as 0.3 in Tel Aviv and 0.4 in Tokyo, Osaka, and Aichi. Moreover, a weighting scheme associated with infectivity results in more accurate forecasting by the infectivity model of viral variants. Results indicate that vaccination effectiveness and infectivity of viral variants are important factors in future forecasting of DPC. Moreover, this study demonstrate a feasible way to project the effect of vaccination using data obtained from other country. |
format | Online Article Text |
id | pubmed-9381972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93819722022-08-17 COVID-19 forecasting using new viral variants and vaccination effectiveness models Rashed, Essam A. Kodera, Sachiko Hirata, Akimasa Comput Biol Med Article Recently, a high number of daily positive COVID-19 cases have been reported in regions with relatively high vaccination rates; hence, booster vaccination has become necessary. In addition, infections caused by the different variants and correlated factors have not been discussed in depth. With large variabilities and different co-factors, it is difficult to use conventional mathematical models to forecast the incidence of COVID-19. Machine learning based on long short-term memory was applied to forecasting the time series of new daily positive cases (DPC), serious cases, hospitalized cases, and deaths. Data acquired from regions with high rates of vaccination, such as Israel, were blended with the current data of other regions in Japan such that the effect of vaccination was considered in efficient manner. The protection provided by symptomatic infection was also considered in terms of the population effectiveness of vaccination as well as the vaccination protection waning effect and ratio and infectivity of different viral variants. To represent changes in public behavior, public mobility and interactions through social media were also included in the analysis. Comparing the observed and estimated new DPC in Tel Aviv, Israel, the parameters characterizing vaccination effectiveness and the waning protection from infection were well estimated; the vaccination effectiveness of the second dose after 5 months and the third dose after two weeks from infection by the delta variant were 0.24 and 0.95, respectively. Using the extracted parameters regarding vaccination effectiveness, DPC in three major prefectures of Japan were replicated. The key factor influencing the prevention of COVID-19 transmission is the vaccination effectiveness at the population level, which considers the waning protection from vaccination rather than the percentage of fully vaccinated people. The threshold of the efficiency at the population level was estimated as 0.3 in Tel Aviv and 0.4 in Tokyo, Osaka, and Aichi. Moreover, a weighting scheme associated with infectivity results in more accurate forecasting by the infectivity model of viral variants. Results indicate that vaccination effectiveness and infectivity of viral variants are important factors in future forecasting of DPC. Moreover, this study demonstrate a feasible way to project the effect of vaccination using data obtained from other country. Elsevier Ltd. 2022-10 2022-08-17 /pmc/articles/PMC9381972/ /pubmed/36030722 http://dx.doi.org/10.1016/j.compbiomed.2022.105986 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Rashed, Essam A. Kodera, Sachiko Hirata, Akimasa COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title | COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title_full | COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title_fullStr | COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title_full_unstemmed | COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title_short | COVID-19 forecasting using new viral variants and vaccination effectiveness models |
title_sort | covid-19 forecasting using new viral variants and vaccination effectiveness models |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381972/ https://www.ncbi.nlm.nih.gov/pubmed/36030722 http://dx.doi.org/10.1016/j.compbiomed.2022.105986 |
work_keys_str_mv | AT rashedessama covid19forecastingusingnewviralvariantsandvaccinationeffectivenessmodels AT koderasachiko covid19forecastingusingnewviralvariantsandvaccinationeffectivenessmodels AT hirataakimasa covid19forecastingusingnewviralvariantsandvaccinationeffectivenessmodels |